Niklaus Kunz has joined Wenger Vieli as senior associate from Bihrer Rechtsanwälte. He is mainly active in the areas of banking and financial market law, capital market law and compliance. He is based in
Tags :Wenger Vieli
As we have informed last 15th December 2022 here, L-GAM, a mid-market private equity investment firm, has invested in Cotta Group, headquartered in Bendern (Liechtenstein), alongside Peter Gschwend. AFINUM has sold its stake in Cotta Collection
Wenger Vieli has announced the appointments of three new partners: Claudia Keller, Patric Eggler and Daniel Oehri (pictured left to right). They will join the partnership of the Swiss law firm as of January 1, 2023 and
Wenger Vieli has advised the lead investor Redalpine Opportunity Fund on all Swiss legal aspects on the closing of Carvolution’s series D financing round. Redalpine is a seed and early-stage venture investor. Car subscription
As we have informed last 3 November 2022 here, Wenger Vieli has also acted as legal and tax advisor to ETH Zurich spin-off LatticeFlow on closing of its USD 12m Series A financing round. The round was
The Swiss ETH spin off Akina receives CHF 1,6 million in pre seed capital. Incorporated by two former members of the SMS Lab, Florian Haufe and Michele Xiloyannis in 2021 after years of research in the areas
Wenger Vieli has advised Swiss Fintech neon on its latest crowd investing campaign and financing round. Neon is an up-and-coming Swiss fintech that has been serving as many as over 130,000 clients already. The company was
Wenger Vieli has advised and assisted CONET Technologies, a portfolio company of IK Partners, in all Swiss legal aspects in connection with the acquisition of emineo, a Swiss IT consulting and software engineering company, with
Wenger Vieli has advised the technology start-up Adresta on all Swiss tax and legal matters during the sale to the Lucerne-based Bucherer. The blockchain start-up Adresta, which is based in Technopark Zurich, will be fully
Wenger Vieli has advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m. NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development
